Viz.ai announced a collaboration with Cortechs.ai to integrate NeuroQuant and NeuroQuant MS into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the United States.
The initiative will begin with a focus on multiple sclerosis, embedding NeuroQuant MS quantitative MRI analysis into Viz.ai’s care coordination workflow to provide clinicians quantitative measurements alongside coordination tools to identify and manage MS patients at scale.
Viz.ai described the move as an expansion of its Viz Neuro Suite into neurodegenerative disease beyond its existing neuro offerings.
According to the company, Viz.ai has an established footprint of nearly 2,000 U.S. hospitals. Cortechs.ai markets NeuroQuant products that the company says are FDA-cleared and designed to quantify and track neurodegenerative and other brain conditions.
The companies said additional partnerships and product announcements focused on neurodegenerative diseases are expected from Viz.ai in the near future.
